Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder

• Published in: International journal of urology 2003-01, Vol.10 (1), p.19-24
• Main Authors: HARA, ISAO, MIYAKE, HIDEAKI, TAKECHI, YOSHIZUMI, ETO, HIROSHI, GOTOH, AKINOBU, FUJISAWA, MASATO, OKADA, HIROSHI, ARAKAWA, SOICHI, KAMIDONO, SADAO
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic - therapeutic use; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic - therapeutic use; BCG Vaccine - therapeutic use; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - pathology; Combined Modality Therapy; Disease-Free Survival; Doxorubicin - analogs & derivatives; Doxorubicin - therapeutic use; Female; grade 3; Humans; instillation of BCG; Male; Middle Aged; Mitomycin - therapeutic use; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; progression; Proportional Hazards Models; recurrence; Retrospective Studies; Risk Factors; superficial bladder cancer; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - pathology
• ISSN: 0919-8172; 1442-2042
• DOI: 10.1046/j.1442-2042.2003.00559.x

Background: The objective of this study was to retrospectively investigate the effectiveness of transurethral resection of bladder tumor (TURBT) and intravesical instillation therapy for stage T1, grade 3 (T1G3) transitional cell carcinoma (TCC) of the urinary bladder. Methods: Between January 1995 and December 1997, 97 patients with T1G3 TCC of the urinary bladder were treated by TURBT and adjuvant intravesical instillation with bacillus Calmette‐Guérin (BCG) or other anticancer agents. The recurrence‐free survival rates were evaluated according to several clinicopathological factors. The cases that progressed to muscle invasive disease were also analysed. Results: In this series, the median follow‐up period was 25 months (range, 5– 41) after the initial TURBT. Intravesical recurrence was noted in 44 patients (45%), and the 1, 2, and 3 year recurrence‐free survival rates were 72%, 58%, and 42%, respectively. Multivariate analyses revealed that the risk of intravesical recurrence was significantly higher for patients who did not receive BCG therapy, irrespective of age, gender, tumor size, multiplicity, pathological stage, concomitant carcinoma in situ, and lymphovascular involvement. Moreover, after a median of 10 months, disease progression occurred in seven patients (7%), of which only one patient was treated by BCG therapy after initial TURBT. Conclusion: These findings suggest that intravesical instillation with BCG combined with TURBT is an effective conservative treatment for T1G3 TCC of the bladder. Patients with negative prognostic factors should be treated by BCG rather than other anticancer agents after TURBT.